...
首页> 外文期刊>Transplantation Proceedings >Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report.
【24h】

Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report.

机译:一名患有急性体液肾移植排斥反应的艾滋病毒患者的单剂量利妥昔单抗联合血浆置换术:一例报道。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Before the highly active antiretroviral therapy (HAART) era, kidney transplantation was not considered an option for patients infected with human immunodeficiency virus (HIV) because of its poor outcome. However, recent studies have demonstrated results comparable to those of recipients without HIV infections. They have shown that HIV-positive patients maintained on HAART mount an immune response. Immunosuppressive agents are chosen to minimize aggravation of HIV infection, bearing in mind the potential side effects of the combination of HAART and immunosuppressive drugs. Herein we have reported the case of a 43-year-old HIV- and hepatitis C virus-infected woman with preserved immune function who received a cadaveric kidney transplant and developed an acute humoral rejection, which was successfully treated with Rituximab.
机译:在高活性抗逆转录病毒疗法(HAART)时代之前,由于人类免疫缺陷病毒(HIV)的预后较差,因此不考虑将肾脏移植用于患者。但是,最近的研究表明结果与没有感染HIV的接受者相当。他们表明,维持HAART的HIV阳性患者会产生免疫反应。考虑到HAART和免疫抑制药物联合使用的潜在副作用,选择免疫抑制剂可最大程度减少HIV感染的恶化。在此,我们报道了一名43岁的艾滋病毒和丙型肝炎病毒感染者,其免疫功能得以维持,该患者接受了尸体肾脏移植并出现了急性体液排斥反应,并成功用利妥昔单抗治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号